Fast Five Quiz: Melanoma Treatment

Chih-Shan Jason Chen, MD, PhD


January 24, 2020

Combination targeted therapy with dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib is recommended by the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) for metastatic or unresectable disease with a BRAF V600 mutation. Current targeted therapies have the potential to slow tumor growth (eg, BRAF inhibition) or release the brakes on the immune response, resulting in tumor lysis (eg, PD-1 inhibition).

Anti–PD-1 monotherapy with pembrolizumab or nivolumab is recommended in this setting for patients who do not have a BRAF V600 mutation.

Interferon alfa-2b was approved in 1995 for adjuvant treatment in patients who at high risk for recurrence after excision. However, although high-dose interferon alfa-2b and pegylated interferon have been shown to improve relapse-free survival, neither improves overall survival.

Access the NCCN Guidelines and Cutaneous Melanoma: ESMO Clinical Practice Guidelines for treatment of cancer.

Learn more about the treatment options for melanoma.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.